Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802208 | 0.84 | SLC6A2 (0.45) | KDM4ESLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL1856673 | 0.84 | SLC6A2 (0.45) | KDM4ESLC6A2SLC6A4HRH1SLC6A3 | |
| Hydrochloric Acid SCHEMBL4728298 | 0.82 | KDM4E (0.44) | KDM4ESLC6A2SLC6A4HRH1SLC6A3 | |
| Hydrochloric Acid SCHEMBL17835794 | 0.82 | KDM4E (0.44) | KDM4ESLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL7269804 | 0.81 | KCNA5 (0.40) | KDM4ESLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL30596267 | 0.81 | KCNA5 (0.51) | KDM4ESLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL6575099 | 0.81 | SLC6A2 (0.42) | KDM4ESLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL2230732 | 0.81 | KCNA5 (0.51) | KDM4ESLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL14353740 | 0.80 | HRH3 (0.47) | KDM4ESLC6A2SLC6A4HRH1SLC6A3 | |
| SCHEMBL3224199 | 0.80 | HRH1 (0.45) | KDM4ESLC6A2SLC6A4HRH1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | NEWAVE PHARMACEUTICAL INC. | 2023-09-21 | — | — | US | disclosed |
| CN-116270660-A | Bcl-2/Bcl-xl inhibitor-containing composition and preparation method and application thereof | 广州麓鹏制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116236583-A | Bcl-2/Bcl-xl inhibitor-containing composition and preparation method and application thereof | 广州麓鹏制药有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4110298-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-115484933-A | Hot melt extrusion solid dispersions containing BCL2 inhibitors | 广州麓鹏制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-1546121-A4 | SUBSTITUTED TRIAZINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1546121-A1 | SUBSTITUTED TRIAZINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004009562-A1 | SUBSTITUTED TRIAZINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | BCL2, BCL2L1, BCL2L2 | KDM4E 2400/4885SLC6A2 2863/4885SLC6A4 3146/4885 |
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | KDM4E 532/4885SLC6A2 4068/4885SLC6A4 4342/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | KDM4E 532/4885SLC6A2 4068/4885SLC6A4 4342/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | KDM4E 722/4885SLC6A2 4672/4885SLC6A4 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.